Source:http://linkedlifedata.com/resource/pubmed/id/10934081
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2 Pt 1
|
pubmed:dateCreated |
2000-9-15
|
pubmed:abstractText |
Platelet-activating factor (PAF) is a potent lipid mediator associated with key features of asthma such as airway constriction, eosinophil infiltration, edema, and mucus accumulation. Regulation of PAF occurs primarily through degradation to biologically inactive lyso-PAF by cellular and secreted PAF-acetylhydrolase (PAF-AH). We evaluated the effect of human recombinant PAF-AH (rPAF-AH) on the dual phase asthmatic response in atopic subjects with mild asthma. Effects on induced sputum cell counts and differentials, eosinophilic cationic protein (ECP), and tryptase were evaluated. Enrolled subjects demonstrated a positive skin test and a dual asthmatic response to allergen inhalation challenge. Fourteen subjects received rPAF-AH (1 mg/kg) or placebo intravenously in a randomized, double blind, placebo-controlled, two-period crossover study. Treatment with rPAF-AH did not significantly reduce either the early- or late-asthmatic response. Sputum eosinophil cell counts were not affected by treatment, but there was a trend toward a reduction in sputum neutrophils. No significant change in sputum ECP and tryptase was observed between rPAF-AH and placebo. Thus, at the dose studied, the unique anti-PAF agent rPAF-AH demonstrated no significant effect on the allergen-induced dual-phase asthmatic response.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Alkyl-2-acetylglycerophosphocholin...,
http://linkedlifedata.com/resource/pubmed/chemical/Allergens,
http://linkedlifedata.com/resource/pubmed/chemical/Phospholipases A,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Activating Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1073-449X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
162
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
523-7
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:10934081-1-Alkyl-2-acetylglycerophosphocholine Esterase,
pubmed-meshheading:10934081-Allergens,
pubmed-meshheading:10934081-Asthma,
pubmed-meshheading:10934081-Cross-Over Studies,
pubmed-meshheading:10934081-Double-Blind Method,
pubmed-meshheading:10934081-Humans,
pubmed-meshheading:10934081-Injections, Intravenous,
pubmed-meshheading:10934081-Phospholipases A,
pubmed-meshheading:10934081-Platelet Activating Factor,
pubmed-meshheading:10934081-Recombinant Proteins
|
pubmed:year |
2000
|
pubmed:articleTitle |
Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses.
|
pubmed:affiliation |
Department of Medicine, University of Washington, Seattle, Washington, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|